

Wei Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3271902/publications.pdf>

Version: 2024-02-01

121
papers

2,394
citations

236612

25
h-index

264894

42
g-index

123
all docs

123
docs citations

123
times ranked

2526
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. <i>The Lancet Global Health</i> , 2019, 7, e861-e871.	2.9	213
2	Evidence-based Guideline for Therapeutic Drug Monitoring of Vancomycin: 2020 Update by the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. <i>Clinical Infectious Diseases</i> , 2020, 71, S363-S371.	2.9	109
3	Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. <i>Archives of Disease in Childhood</i> , 2013, 98, 449-453.	1.0	104
4	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1068-1080.	1.1	92
5	Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. <i>European Journal of Pediatrics</i> , 2020, 179, 839-847.	1.3	84
6	Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in china with or without specific fusion transcripts: A single institutional study of 1,004 patients. <i>American Journal of Hematology</i> , 2012, 87, 1022-1027.	2.0	65
7	Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey. <i>Archives of Disease in Childhood</i> , 2015, 100, 394-398.	1.0	65
8	Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1273-1285.	1.6	65
9	Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3191-3199.	1.4	62
10	Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1280-1291.	1.0	61
11	Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. <i>Seminars in Fetal and Neonatal Medicine</i> , 2013, 18, 28-34.	1.1	59
12	Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 189-195.	0.8	56
13	Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2039-2042.	1.4	44
14	Population Pharmacokinetics of Ciprofloxacin in Neonates and Young Infants Less than Three Months of Age. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6572-6580.	1.4	41
15	Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1197-1207.	1.1	41
16	Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 454-464.	1.1	38
17	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 992-1002.	1.3	37
18	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 358-366.	1.1	34

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2128-2138.	1.3	33
20	Developmental Pharmacogenetics of Immunosuppressants in Pediatric Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 688-699.	1.0	32
21	Principles of Therapeutic Drug Monitoring. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 77-90.	0.9	29
22	Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1127-1134.	1.6	29
23	Choosing the right dose of tacrolimus. <i>Archives of Disease in Childhood</i> , 2015, 100, 406-413.	1.0	29
24	Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	29
25	How to use vancomycin optimally in neonates: remaining questions. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 635-648.	1.3	28
26	Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1748-1756.	1.1	27
27	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. <i>Antiviral Therapy</i> , 2010, 15, 297-305.	0.6	26
28	A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6626-6634.	1.4	26
29	Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1989-1999.	1.1	26
30	Population Pharmacokinetics of Ganciclovir Following Administration of Valganciclovir in Paediatric Renal Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 321-328.	1.6	25
31	Cystatin C as a potential biomarker for dosing of renally excreted drugs. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 20-27.	1.1	25
32	Optimisation of vancomycin exposure in neonates based on the best level of evidence. <i>Pharmacological Research</i> , 2020, 154, 104278.	3.1	25
33	Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 681-687.	1.0	23
34	Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates. <i>Biomedical Chromatography</i> , 2011, 25, 827-832.	0.8	22
35	Individualization of Valganciclovir Prophylaxis for Cytomegalovirus Infection in Pediatric Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 326-330.	1.0	21
36	Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	21

#	ARTICLE	IF	CITATIONS
37	Current knowledge, challenges and innovations in developmental pharmacology: A combined connect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4965-4984.	1.1	21
38	Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	20
39	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1435-1448.	1.6	20
40	Commentary on the MID3 Good Practices Paper. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 416-417.	1.3	18
41	Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants. <i>Frontiers in Pharmacology</i> , 2020, 11, 14.	1.6	18
42	Covariate effects and population pharmacokinetics of lamivudine in <sc>HIV</sc>-infected children. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 861-872.	1.1	17
43	Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug-Induced Hepatotoxicity in Chinese Pediatric Patients. <i>PLoS ONE</i> , 2014, 9, e115410.	1.1	17
44	Developmental pharmacogenetics of <sc>CYP2C19</sc> in neonates and young infants: omeprazole as a probe drug. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 997-1005.	1.1	16
45	Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	16
46	Safety study of Ciprofloxacin in newborn mice. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 74, 161-169.	1.3	15
47	Population Pharmacokinetics of Ganciclovir after Valganciclovir Treatment in Children with Renal Transplant. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	15
48	First Dose in Neonates: Are Juvenile Mice, Adults and In Vitro-In Silico Data Predictive of Neonatal Pharmacokinetics of Fluconazole. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1005-1018.	1.6	14
49	Dosage individualization in children: integration of pharmacometrics in clinical practice. <i>World Journal of Pediatrics</i> , 2014, 10, 197-203.	0.8	14
50	Pharmacogenetic Determinant of the Drug Interaction Between Tacrolimus and Omeprazole. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 739-741.	1.0	13
51	Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1181-1185.	0.8	13
52	Population pharmacokinetics of abacavir in infants, toddlers and children. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1525-1535.	1.1	13
53	Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. <i>Acta Pharmacologica Sinica</i> , 2013, 34, 969-975.	2.8	13
54	Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1519-1527.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0089721.	1.4	13
56	Pharmacokinetic Interaction Between Tacrolimus and Amlodipine in a Renal Transplant Child. <i>Transplantation</i> , 2012, 93, e29-e30.	0.5	12
57	Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
58	Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
59	Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus. <i>Medicine (United States)</i> , 2020, 99, e23212.	0.4	12
60	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	11
61	Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1155-1164.	1.1	11
62	Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 699-709.	1.3	11
63	Population pharmacokinetics and maximum <i>a posteriori</i> probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 641-650.	1.1	10
64	Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. <i>Pediatric Nephrology</i> , 2018, 33, 1045-1055.	0.9	10
65	Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study. <i>Archives of Disease in Childhood</i> , 2018, 103, 772-775.	1.0	10
66	Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 347-351.	1.1	10
67	The Importance of Knowing How Vancomycin is Measured When Interpreting Its Pharmacokinetic Results. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 416.	1.0	8
68	Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. <i>Drug Design, Development and Therapy</i> , 2014, 8, 2321.	2.0	8
69	Determination of cefoperazone and sulbactam in serum by HPLC-MS/MS: An adapted method for therapeutic drug monitoring in children. <i>Biomedical Chromatography</i> , 2018, 32, e4143.	0.8	8
70	Early target attainment of azithromycin therapy in children with lower respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2846-2850.	1.3	8
71	Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	8
72	Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate. <i>Frontiers in Pharmacology</i> , 2020, 11, 566060.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1633-1640.	2.0	8
74	Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	7
75	Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 274-284.	1.1	7
76	A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 852-860.	1.1	6
77	Pharmacokinetics and dosage individualization of ganciclovir and valganciclovir in an infant with nephrotic syndrome associated with cytomegalovirus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1150-1151.	1.3	6
78	A microscale HPLC-UV method for the determination of latamoxef in plasma: An adapted method for therapeutic drug monitoring in neonates. <i>Biomedical Chromatography</i> , 2018, 32, e4243.	0.8	6
79	Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
80	Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1547-1556.	0.8	6
81	Paediatric drugs trials in China. <i>BMJ Paediatrics Open</i> , 2020, 4, e000618.	0.6	6
82	Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1917-1924.	1.3	6
83	An adapted LC-MS/MS method for the determination of free plasma concentration of cefoperazone in children: Age-dependent protein binding. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1144, 122081.	1.2	6
84	A simplified method for bortezomib determination using dried blood spots in combination with liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1181, 122905.	1.2	6
85	Optimizing Micafungin Dosing in Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1211-1212.	1.1	5
86	Oral drugs used to treat persistent pulmonary hypertension of the newborn. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1295-1308.	1.3	5
87	Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	5
88	Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Chinese Infants. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 538-546.	1.0	5
89	Population Pharmacokinetic Study of Cefthiamidone in Infants With Augmented Renal Clearance. <i>Frontiers in Pharmacology</i> , 2021, 12, 630047.	1.6	5
90	Downregulation of Renal MRPs Transporters in Acute Lymphoblastic Leukemia Mediated by the IL-6/STAT3/PXR Signaling Pathway. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2239-2252.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105868.	1.9	5
92	Optimal dose of meropenem for the treatment of neonatal sepsis: Dosing guideline variations and clinical practice deviations. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3483-3489.	1.1	5
93	Population pharmacokinetics and dosing optimization of cefthiamidine in children with hematologic infection. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 855-862.	2.0	4
94	Body Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
95	Drug Elimination Alteration in Acute Lymphoblastic Leukemia Mediated by Renal Transporters and Glomerular Filtration. <i>Pharmaceutical Research</i> , 2020, 37, 158.	1.7	4
96	First dose in neonates: pharmacokinetic bridging study from juvenile mice to neonates for drugs metabolized by CYP3A. <i>Xenobiotica</i> , 2020, 50, 1275-1284.	0.5	4
97	Serum Creatinine and Serum Cystatin C are Both Relevant Renal Markers to Estimate Vancomycin Clearance in Critically Ill Neonates. <i>Frontiers in Pharmacology</i> , 2021, 12, 634686.	1.6	4
98	Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1027-1038.	1.6	4
99	Principles and applications of pharmacometrics in drug evaluation in children. <i>Therapie</i> , 2018, 73, 165-170.	0.6	3
100	<p>Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4405-4411.	2.0	3
101	Latamoxef for Neonates With Early-Onset Neonatal Sepsis: A Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 635517.	1.6	3
102	Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. <i>Clinical Pharmacokinetics</i> , 2022, 61, 71-81.	1.6	3
103	CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 692922.	1.6	3
104	LPS-Induced Inflammation Affects Midazolam Clearance in Juvenile Mice in an Age-Dependent Manner. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3697-3706.	1.6	3
105	Authorâ€™s Reply to Standing et al. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1289-1291.	1.6	2
106	Pharmacokinetics and safety of pegylated recombinant human granulocyte colonyâ€™stimulating factor in children with acute leukaemia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3292-3300.	1.1	2
107	Offâ€™label use of letrozole in Chinese short pubertal boys: Effectiveness, safety, and exposureâ€™response analysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3599-3607.	1.1	2
108	Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug. <i>Frontiers in Pharmacology</i> , 2021, 12, 657287.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Determination of Loratadine and Its Active Metabolite in Plasma by LC/MS/MS: An Adapted Method for Children. <i>Current Pharmaceutical Analysis</i> , 2020, 16, 909-915.	0.3	2
110	Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	1.3	2
111	Cefotiam Treatment in Children: Evidence of Subtherapeutic Levels. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 733-736.	1.0	1
112	PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00574.	1.1	1
113	Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 74-77.	0.7	1
114	Effects of continuous venovenous hemofiltration on vancomycin trough concentrations in critically ill children. <i>Annals of Translational Medicine</i> , 2021, 9, 224-224.	0.7	1
115	A Validated LC-MS/MS Method for the Determination of Mezlocillin in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children. <i>Current Pharmaceutical Analysis</i> , 2021, 17, 853-860.	0.3	1
116	Clinical utility of a model-based piperacillin dose in neonates with early-onset sepsis. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	1
117	Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease. <i>Blood</i> , 2017, 130, 975-975.	0.6	1
118	A Sensitive Microscale HPLC-UV Method for the Determination of Doxofylline and its Metabolites in Plasma: An Adapted Method for Therapeutic Drug Monitoring in Children. <i>Current Pharmaceutical Analysis</i> , 2019, 16, 47-54.	0.3	1
119	Aciclovir CSF concentration in children with viral encephalitis: is it adequate?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2582-2583.	1.3	0
120	Editorial: Model-Based Evaluation of Antimicrobial Agents in Children. <i>Frontiers in Pharmacology</i> , 2021, 12, 731209.	1.6	0
121	Optimal Sample Size for Use in Neonatal Pharmacokinetic Studies. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, , 1.	0.8	0